Featured
Read our handpicked blogs, curated for you.
|
Why the pharma marketing stack is a boardroom issue now? You might think that! Well, Indian pharma has always been…
|
CMOs do not struggle to justify campaigns; they struggle to prove Marketing ROI with hard numbers the board trusts. If…
|
Pharma marketers in India know the frustration well. Campaigns stall not because the idea is weak, but because the…
Recent releases
|
Why pharma marketing still flies blind in India
Indian pharma marketing is at a crossroads. Budgets are rising, regulations are tightening, and digital adoption is accelerating. Yet when senior leaders are asked the simplest boardroom question: “…
|
The cost of slow content in pharma marketing and how to amplify it
Every pharma marketer knows the story. A campaign is planned around a new therapy, the slides are drafted, medical-legal-regulatory begins its review, weeks pass, edits keep coming back, and by the…
|
UCPMP 2024 changes pharma marketers must act on
For years, pharma marketing in India carried a reputation for being stuck between outdated field-force practices and patchy digital adoption. That space has shifted. UCPMP 2024 is not just an update…
|
AI-Powered Pharma Market Access: Tier 2 and Tier 3 Strategy
Pharma market access in India has shifted. Growth in metros is plateauing, competition is fierce, and doctors in top cities are over-engaged. The next wave lies in Tier 2 and Tier 3 India, where…
